Literature DB >> 1738091

Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding.

C Lekutis1, U Olshevsky, C Furman, M Thali, J Sodroski.   

Abstract

The carboxyl half of the HIV-1 gp120 glycoprotein, which has been implicated in binding to the CD4 receptor, contains two disulfide bonds linking cysteine residues 378-445 and 385-418. To examine the necessity of these disulfide bonds for the formation and/or maintenance of a gp120 glycoprotein competent for CD4 binding, we created mutants of a soluble form of gp120 in which combinations of these cysteine residues were altered. The mutant glycoproteins were examined for export from the expressing cell and for CD4 binding ability. Mutant gp120 molecules lacking both disulfide bonds were not stably expressed or exported. However, mutants for which either disulfide bond could form were exported and were fully competent for CD4 binding. In some cases, the presence of one of the pair of linked cysteines exerted more detrimental effects on export or CD4 binding than did alteration of both cysteines. Thus, the evaluation or the contribution of a particular disulfide bond to a phenotype should include studies in which both cysteines involved in the bond are simultaneously altered.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738091

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  7 in total

1.  Only five of 10 strictly conserved disulfide bonds are essential for folding and eight for function of the HIV-1 envelope glycoprotein.

Authors:  Eelco van Anken; Rogier W Sanders; I Marije Liscaljet; Aafke Land; Ilja Bontjer; Sonja Tillemans; Alexey A Nabatov; William A Paxton; Ben Berkhout; Ineke Braakman
Journal:  Mol Biol Cell       Date:  2008-07-23       Impact factor: 4.138

2.  CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.

Authors:  P J Klasse; M M Rosenkilde; N Signoret; A Pelchen-Matthews; T W Schwartz; M Marsh
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

3.  Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction.

Authors:  H J Ryser; E M Levy; R Mandel; G J DiSciullo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

4.  Mode of antiviral action of silver nanoparticles against HIV-1.

Authors:  Humberto H Lara; Nilda V Ayala-Nuñez; Liliana Ixtepan-Turrent; Cristina Rodriguez-Padilla
Journal:  J Nanobiotechnology       Date:  2010-01-20       Impact factor: 10.435

5.  Disulfide bond structure of glycoprotein D of herpes simplex virus types 1 and 2.

Authors:  D Long; W C Wilcox; W R Abrams; G H Cohen; R J Eisenberg
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  Amplification of a complete simian immunodeficiency virus genome from fecal RNA of a wild chimpanzee.

Authors:  Mario L Santiago; Frederic Bibollet-Ruche; Elizabeth Bailes; Shadrack Kamenya; Martin N Muller; Magdalena Lukasik; Anne E Pusey; D Anthony Collins; Richard W Wrangham; Jane Goodall; George M Shaw; Paul M Sharp; Beatrice H Hahn
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 7.  "Fusion and binding inhibition" key target for HIV-1 treatment and pre-exposure prophylaxis: targets, drug delivery and nanotechnology approaches.

Authors:  Tanushree Malik; Gaurav Chauhan; Goutam Rath; R S R Murthy; Amit K Goyal
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.